news
Retatrutide trial shows up to 25% weight loss with triple-hormone drug
Eli Lilly's experimental drug Retatrutide, which targets GLP-1, GIP, and glucagon receptors, helped participants lose up to 25% of their body weight in a Phase 2 trial. This triple-agonist approach suggests a potent effect on metabolism and blood sugar regulation. It could be a new tier in obesity and metabolic care.
Eli Lilly's experimental drug Retatrutide, which targets GLP-1, GIP, and glucagon receptors, helped participants lose up to 25% of their body weight in a Phase 2 trial. This triple-agonist approach suggests a potent effect on metabolism and blood sugar regulation. It could be a new tier in obesity and metabolic care.
The architecture take
So, 25% body weight loss, thanks to a drug that hits three different metabolic pathways? That's not just a bigger number; it's a different kind of metabolic conversation. The GLP-1 story was already a game-changer for blood sugar and appetite. Adding GIP helps fine-tune insulin response and glucagon seems to speed up energy expenditure. I keep watching these trials because they push on how we think about fat storage, not as a willpower problem, but as something driven by deep-seated hormonal signaling. We're getting closer to drugs that actually reprogram the body's energy balance. It means the "eat less, move more" advice is going to sound even more hollow for some people. I wonder what the long-term data will say about maintaining these losses. That's the real test.